Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Breast Cancer

New options in advanced breast cancer

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
  • 3 minute read

While new lecture formats had to be established due to the Corona pandemic, substantial progress in research around cancer therapies remained constant, as evidenced by study results presented at EHA. In the area of breast cancer in particular, there were exciting new developments that could improve the prognosis of those affected and provide food for thought.

Approximately 15 to 20 percent of all patients with breast cancer have overexpression of the HER2 protein (Human Epidermal Growth Factor Receptor 2), which is associated with aggressive disease progression and poor prognosis. However, researchers have now found that 55-60% of HER2-negative patients do express low levels of HER2. Trastuzumab is a recombinant, humanized monoclonal antibody directed against the extracellular domain of HER2/neu on breast carcinoma cells. Due to its good efficacy, the IgG1 antibody is indicated in all stages of HER2-positive breast cancer. Progression-free survival (PFS) and overall survival may be extended in a clinically relevant manner.

Now, recent study results of different combinations with trastuzumab have been presented. For example, the antibody-drug conjugate (ADC) trastuzumab-deruxtecan (T-DXd) has demonstrated efficacy over standard chemotherapy in pretreated patients with unresectable and/or metastatic breast cancer with low HER2 expression (HER2-low) and hormone receptor-positive or -negative disease (HR+/-). In a phase III trial, 557 affected individuals randomized 2:1 to receive either T-DXd or chemotherapy of the investigator’s choice. The primary endpoint was PFS in HR+ HER2-low tumors, and secondary endpoints were PFS in the overall cohort and overall survival (OS). After a median follow-up of 18.4 months, the median PFS among those with HR+ HER2-low- breast cancer treated with T-DXd versus chemotherapy was 10.1 months vs. 5.4 months. Accordingly, the risk of disease progression or death was reduced by 49% compared with chemotherapy. The situation was similar in the overall population. For OS, study results were similar for the overall cohort (23.4 vs. 6.8 months) and HR-negative population (18.2 vs. 8.3 months). For the first time, a therapy targeting HER2 has shown a survival benefit in patients with low HER2 expression. This suggests that the way patients with metastatic breast cancer are categorized should be reconsidered.

Endocrine pretreated HR+/HER2- tumors.

The ADC sacituzumab govitecan (SG), which targets the overexpressed surface antigen Tro-2, is recommended in current treatment guidelines as the preferred treatment option for advanced or metastatic triple-negative breast carcinoma (mTNBC) starting in the second line of therapy. Now it has been compared to conventional chemotherapy in endocrine-pretreated patients with HR+/HER2-negative tumors, the most common subtype in metastatic breast cancer. All patients also had prior taxane and CDK4/6 inhibitor therapy. Median PFS was significantly prolonged at 5.5 months versus 4.0 months in the control arm after a median observation period of 10.2 months in the SG arm. This represents a 34% risk reduction for disease progression or death. In addition, the response rate was significantly higher in the ADC arm (52.6%) than in the comparator arm (16.3%) with a known toxicity profile. Only 6% of sufferers in the experimental arm versus 4% of the control group discontinued treatment due to treatment-associated adverse events of grade 3 or greater. Quality of life also deteriorated significantly more slowly under the influence of SG (4.0 months vs. 2.9 months).

Therapy in oligometastatic breast carcinoma

In oligometastatic breast carcinoma, we investigated whether targeted treatment of metastases with stereotactic radiation and/or surgical resection could provide additional benefit to those affected. Patients with up to four metastases (excluding brain metastases) and stable disease on ongoing systemic therapy were included regardless of breast carcinoma subtype. However, supplemental quality-assured treatment did not improve clinical outcome in terms of PFS and OS.

Congress: EHA 2022

InFo ONCOLOGY & HEMATOLOGY 2022; 10(4): 32.

Autoren
  • Leoni Burggraf
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Breast Cancer
  • Breast Cancer
  • EHA
  • HR+
  • PFS
Previous Article
  • Iron deficiency

Ferritin standard values vary according to patient population

  • Cardiology
  • Congress Reports
  • General Internal Medicine
  • Hematology
  • RX
View Post
Next Article
  • AID systems

Improved therapy for type 1 diabetes with new devices

  • Congress Reports
  • Endocrinology and Diabetology
  • General Internal Medicine
  • Partner Content
  • Prevention and health care
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 2 min
  • Chronic pain

Nano-ECS modulator Adezunap improves therapy success

    • Congress Reports
    • General Internal Medicine
    • Pharmaceutical medicine
    • Pharmacology and toxicology
    • Phytotherapy
    • Rheumatology
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis and PsA

Biologics, oral peptide and trivalent nanobody – current results and trends

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Rheumatology
    • RX
    • Studies
View Post
  • 5 min
  • Cancer in Europe: facts and analysis

New Health Policy Report published

    • General Internal Medicine
    • Oncology
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 4 min
  • Gastrointestinal complaints

PPI regulation under the microscope

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 6 min
  • Wound management: clinical diagnostics

Assessing the risk of infection – from the ABCDE to the TILI score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Infectiology
    • Interviews
    • Physical medicine and rehabilitation
    • Prevention and health care
    • RX
View Post
  • 4 min
  • Study report

Digital patient education for atrial fibrillation shows measurable effects

    • Cardiology
    • Education
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 4 min
  • New practice guideline for fibromyalgia syndrome

Good times, bad times

    • Congress Reports
    • General Internal Medicine
    • Neurology
    • Pharmacology and toxicology
    • Physical medicine and rehabilitation
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 23 min
  • Important basics and studies on cancer and the psyche

Interplay between cancer and mental illness

    • CME continuing education
    • Oncology
    • Psychiatry and psychotherapy
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    How combination therapies lead to better treatment results
  • 2
    Interplay between cancer and mental illness
  • 3
    PH and lung diseases
  • 4
    Treatment of comorbidities in older people
  • 5
    Multidisciplinary teams in oncology

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.